Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects-Reference-Cited by-同舟云学术

Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects

Published:2022-02-19 Issue:4 Volume:11 Page:442-453
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Chimalakonda Anjaneya¹,Singhal Shalabh¹,Darbenzio Raymond¹,Dockens Randy¹,Marchisin David¹,Banerjee Subhashis¹,Girgis Ihab G.¹,Throup John¹,He Bing¹,Aras Urvi¹,Murthy Bindu¹

Affiliation:

1. Bristol Myers Squibb Princeton New Jersey USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1056

Reference23 articles.

1. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain

2. Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain

3. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

4. ChimalakondaA ArasU YaoM et al.Pharmacokinetics and ADME characteristics of a selective TYK2 inhibitor BMS‐986165 following oral administration in healthy subjects [poster PIII‐027].Presented at: the Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; March 13‐16 2019;Washington DC.

5. A first‐in‐human, study of BMS‐986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2 [abstract SAT0226;Catlett I;Ann Rheum Dis,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deucravacitinib: moderate-to-severe plaque psoriasis preventable?;Journal of Basic and Clinical Physiology and Pharmacology;2024-07-09

2. Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities;Dermatology and Therapy;2024-04

3. Absolute and Relative Bioavailability of Oral Solid Dosage Formulations of Deucravacitinib in Humans;Clinical Pharmacology in Drug Development;2023-08-16

4. Progress on the Pharmacological Targeting of Janus Pseudokinases;Journal of Medicinal Chemistry;2023-08-14

5. Fast and Sensitive Bioanalytical Method for the Determination of Deucravacitinib in Human Plasma Using HPLC-MS/MS: Application and Greenness Evaluation;Molecules;2023-07-17